>
Dr. Chen during glioblastoma neurosurgery procedure at UCLA.
In a gripping new episode of New Frontiers by Planet TV Studios, viewers are taken inside the revolutionary world of NeOnc Technologies Holdings, Inc., a biotech company redefining the battle against aggressive brain cancers. At the heart of this transformation is Dr. Thomas Chen, Director of Surgical Neuro-Oncology at USC and NeOnc’s founder. The episode showcases how Dr. Chen’s lifelong mission to help patients with brain cancer has led to the development of a non-invasive intranasal drug delivery system that bypasses the blood-brain barrier (BBB)—a breakthrough that could change the future of neuro-oncology forever.
Planet TV Host Gina Grad
Hosted by Gina Grad, the episode highlights the science and humanity driving NeOnc’s efforts. Through engaging interviews and on-the-ground reporting, New Frontiers> explores how NeOnc’s therapies—particularly NEO100, a purified form of perillyl alcohol, and NEO212, a novel drug combining perillyl alcohol with TMZ—offer precise, targeted treatments for patients suffering from deadly conditions like glioblastoma multiforme. These patented therapies are designed not only to improve survival rates but also to minimize the harsh side effects typically associated with brain cancer treatments.
The documentary delves into how intranasal drug delivery is becoming a game-changing method for reaching the brain without surgery, IVs, or hospital stays. By leveraging the body’s own cranial nerve pathways, NeOnc’s platform allows cancer-fighting compounds to reach their targets efficiently, safely, and often from the comfort of the patient’s home. This segment also gives viewers a glimpse into the real-world impact of these advancements, featuring testimonies from patients who have experienced extended survival and improved quality of life.
In addition to its scientific breakthroughs, the episode spotlights NeOnc’s commitment to ethical research and patient-centered care. Dr. Chen’s team combines rigorous clinical methodology with a deep understanding of patient needs, ushering in a new era of personalized medicine and minimally invasive neurosurgery. These values are particularly critical as the company prepares for its direct listing on Nasdaq in Q1 2025, signaling a new phase of growth and visibility in the biotech sector.
Set to air nationwide in Q2/Q3 2025, New Frontiers: The Future of Neurosurgery will also be available on-demand across Amazon, YouTube, Vimeo, Facebook, and Roku, making this extraordinary story accessible to a global audience. With the spotlight on NeOnc’s innovations, this episode presents a compelling vision of what happens when world-class science meets compassion, ingenuity, and hope.